# Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia

> **NCT05554913** · PHASE2,PHASE3 · COMPLETED · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 63 (actual)

## Conditions studied

- Chemotherapy-induced Thrombocytopenia

## Interventions

- **DRUG:** QL0911
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05554913
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-08
- **Primary completion:** 2024-02-20
- **Final completion:** 2024-02-20
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05554913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05554913, "Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05554913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*